Explore

TrendlineTrendline
Pfizer Advances GLP-1 Drug Development with Focus on Monthly Dosing

Pfizer Advances GLP-1 Drug Development with Focus on Monthly Dosing

Pfizer Advances GLP-1 Drug Development with Focus on Monthly Dosing
Rapid ReadRapid Read
Johnson Johnson Announces Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis Treatment

Johnson Johnson Announces Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis Treatment

Johnson & Johnson has announced positive results from a Phase 3 investigational study for its drug ICOTYDE (icotrokinra) in treating biologic-naive adults with active psoriatic arthritis (PsA). The late-breaking data, presented at the American College of Rheumatology (ACR) Convergence 2026, showed that 58% of patients treated with ICOTYDE achieved an ACR20 response at Week 16, compared to 41% receiving a placebo. Furthermore, 29% achieved an ACR50 response. ICOTYDE is described as the first and only targeted oral peptide that precisely blocks the IL-23 receptor, a key driver of inflammation in psoriatic diseases. The study also reported significant improvements in skin involvement, with 57% of patients achieving clear or almost clear skin (Investigator's Global Assessment 0/1) and 37% achieving a Psoriasis Area and Severity Index (PASI) score of 90, compared to placebo groups. Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified through Week ...
Rapid ReadRapid Read
Medable Platform Advances Decentralized Clinical Trials with FDA Compliance and Enhanced Data Integrity

Medable Platform Advances Decentralized Clinical Trials with FDA Compliance and Enhanced Data Integrity

Medable, a cloud-based eClinical software platform, is facilitating decentralized clinical trials (DCTs) and hybrid clinical studies by digitizing protocol workflows. This platform enables remote electronic informed consent (eConsent), electronic clinical outcome assessments (eCOA/ePRO), and virtual patient visits, aligning with the U.S. Food and Drug Administration (FDA) Guidance for Industry on Conducting Clinical Trials With Decentralized Elements, published in September 2024. Medable's system ensures compliance with FDA 21 CFR Part 11 for electronic records and signatures, as well as Good Clinical Practice (GCP) data integrity standards. The platform serves sponsors, contract research organizations (CROs), site investigators, coordinators, study participants, and local healthcare providers, allowing for remote data capture and management through mobile apps, web portals, and connected devices. This approach aims to reduce the need for participants to visit physical clinics for every aspect of a trial, ...
TrendlineTrendline
China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials
Rapid ReadRapid Read
FDA Scrutiny on Clinical Trial Extension Studies Intensifies for Long-Term Drug Safety

FDA Scrutiny on Clinical Trial Extension Studies Intensifies for Long-Term Drug Safety

The U.S. Food and Drug Administration (FDA) is increasing its focus on the necessity of extension studies in clinical trials, particularly for chronic diseases, oncology, and gene therapies. A recent JAMA analysis highlights that most pivotal trials are designed to measure primary endpoints at fixed timepoints, often failing to assess sustained treatment benefits or detect rare, delayed adverse events that may manifest years after initial approval. This gap in data collection can lead to an inadequate understanding of a drug's long-term safety and efficacy. The FDA's stance, aligning with ICH E1 guidelines, emphasizes that long-term safety data should follow pivotal submissions, not precede them. Sponsors who do not pre-specify extension sample size requirements, retention strategies, and estimand frameworks before the pivotal trial begins risk negotiating with an insufficient dataset, potentially leading to constrained drug labels.
TrendlineTrendline
Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline
TrendlineTrendline
AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges
TrendlineTrendline
MRM Health and Biocodex Partner to Enhance Commercial Supply for Microbiome-Based Medicines

MRM Health and Biocodex Partner to Enhance Commercial Supply for Microbiome-Based Medicines

MRM Health and Biocodex Partner to Enhance Commercial Supply for Microbiome-Based Medicines
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
Rapid ReadRapid Read
Anaheim Bio Launches with €40 Million Series A to Advance ANA-1 for CPPD Disease

Anaheim Bio Launches with €40 Million Series A to Advance ANA-1 for CPPD Disease

Anaheim Bio, a new preclinical-stage biotechnology company, has officially launched with an oversubscribed €40 million Series A financing round. The funding will be used to advance ANA-1, its lead small molecule therapeutic candidate, for the treatment of calcium pyrophosphate deposition disease (CPPD). ANA-1 is designed to directly address the underlying pathology of CPPD by lowering extracellular pyrophosphate (PPi), which is responsible for the crystal deposits that cause the inflammatory arthritis. CPPD primarily affects older adults, causing severe joint pain and swelling, and currently lacks an approved therapy that targets the crystal deposits themselves. Anaheim Bio, spun out of Alesta Therapeutics, is backed by Alesta's former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest, and Thuja Capital. The company anticipates ANA-1 will enter clinical trials in 2027, with the Series A financing providing runway into 2028.
Rapid ReadRapid Read
Novartis-Sponsored Drug Pelacarsen Fails to Prevent Heart Attacks and Strokes in Crucial Study

Novartis-Sponsored Drug Pelacarsen Fails to Prevent Heart Attacks and Strokes in Crucial Study

An experimental drug, pelacarsen, designed to reduce levels of lipoprotein(a) (Lp(a)) in the blood, unexpectedly failed to prevent heart attacks and strokes in a major study. The research, led by cardiologist Steven Nissen of the Cleveland Clinic, involved 8,350 adults with existing heart disease who were given either pelacarsen or a placebo. While the drug successfully suppressed Lp(a) levels by approximately 78%, this reduction did not translate into a decrease in cardiovascular complications over a five-year period. The findings were presented at an American Heart Association meeting in Chicago and published in the New England Journal of Medicine and NEJM Evidence. Drugmaker Novartis, which sponsored the study, had previously announced the study did not meet its goals without releasing specific details, stating only that it provided 'meaningful evidence' about the relationship between Lp(a) and heart disease.
TrendlineTrendline
Biocodex Invests €15 Million in New Industrial Platform for Live Biotherapeutic Products in France

Biocodex Invests €15 Million in New Industrial Platform for Live Biotherapeutic Products in France

Biocodex Invests €15 Million in New Industrial Platform for Live Biotherapeutic Products in France